Migraine

AUSTIN, Texas — The use of remote electrical neuromodulation in adolescents with acute migraine was safe and efficacious as a nonpharmacological treatment option, according to a poster presented here.

AUSTIN, Texas — Significant improvement was reported in children who have follow-up visits to a headache clinic, although Black patients and patients on Medicaid were less likely to complete these visits, according to data presented here.

AUSTIN, Texas — Specialty office visits for chronic migraine were significantly reduced in individuals who participated in a group telemedicine program, according to research presented at the American Headache Society’s annual meeting.

The FDA has accepted for review a 505(b)(2) new drug application for STS101, a novel, investigational nasal powder for the acute treatment of migraine.

BOSTON — Intranasal Zavzpret was safe and effective for acute treatment of migraine, providing pain relief as early as 15 minutes after administration, according to a presenter at the American Academy of Neurology annual meeting.

BOSTON — Fewer patients who took ubrogepant during the premonitory phase went on to have headache when compared with placebo, Peter Goadsby, MD, PhD, FRS, said in this Healio video at the American Academy of Neurology annual meeting.

As allergies emerge each spring, so do migraines. The American Migraine Foundation says that 37% of people with allergies also have migraines, compared with 5% of people who do not have allergies, in an association that increases with age.

NEW YORK — Avulux announced the U.S. availability of its new spectacle lens designed to block the majority of the light spectrum that has been shown to be harmful to migraine sufferers.

The FDA approval of Zavzpret, which Pfizer announced in March 2023, is good news for people living with migraine, as it becomes an important option to help combat this disease.

Treatment with zavegepant 10 mg nasal spray was safe, well-tolerated and provided pain and symptom relief for moderate to severe migraine compared with placebo, according to a study published in The Lancet Neurology.